PMID- 38537621
OWN - NLM
STAT- MEDLINE
DCOM- 20240424
LR  - 20240424
IS  - 1664-5502 (Electronic)
IS  - 1664-5502 (Linking)
VI  - 14
IP  - 1
DP  - 2024
TI  - Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in 
      Patients with Chronic Kidney Disease.
PG  - 227-234
LID - 10.1159/000538347 [doi]
AB  - BACKGROUND: The mineralocorticoid receptor plays an important pathophysiological 
      role in cardiorenal diseases by causing inflammation and fibrosis. 
      Mineralocorticoid receptor antagonists (MRAs) are well known in treating 
      cardiovascular disease and diverse nephropathies. However, the first-generation 
      MRA (spironolactone) and the second-generation MRA (eplerenone) remain 
      underutilized because of the risk of inducing severe adverse events. As a 
      selective nonsteroidal MRA, finerenone is safer and more effective and improves 
      cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 
      diabetes mellitus (T2DM). However, the effect of finerenone on cardiorenal 
      outcomes in patients of different races and kidney function (estimated glomerular 
      filtration rate) is unclear. SUMMARY: In this review, we summarized the impact of 
      finerenone on patients with CKD and T2DM from randomized controlled trials. The 
      synthesis of published data aims to address the questions pertaining to the 
      cardiorenal benefits of finerenone among various racial groups and different 
      levels of kidney function. KEY MESSAGE: Finerenone presents racial differences 
      and effects associated with kidney function in CKD and T2DM patients. Due to the 
      limited data for subgroups, it is prudent to approach the conclusion with 
      caution.
CI  - (c) 2024 The Author(s). Published by S. Karger AG, Basel.
FAU - Li, Pingjiang
AU  - Li P
AD  - Department of Endocrinology and Metabology, The First Affiliated Hospital of 
      Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, 
      Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong 
      Institute of Nephrology, Jinan, China.
AD  - Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, China.
FAU - Cui, Yuying
AU  - Cui Y
AD  - Department of Endocrinology and Metabology, The First Affiliated Hospital of 
      Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, 
      Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong 
      Institute of Nephrology, Jinan, China.
AD  - First Clinical Medical College, Shandong University of Traditional Chinese 
      Medicine, Jinan, China.
FAU - Xu, Xiaoming
AU  - Xu X
AD  - Department of Endocrinology and Metabology, The First Affiliated Hospital of 
      Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, 
      Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong 
      Institute of Nephrology, Jinan, China.
AD  - Department of Endocrinology and Metabology, Shandong Provincial Qianfoshan 
      Hospital, Shandong University, Shandong Key Laboratory of Rheumatic Disease and 
      Translational Medicine, Shandong Institute of Nephrology, Jinan, China.
FAU - Dong, Jianjun
AU  - Dong J
AD  - Division of Endocrinology, Department of Internal Medicine, Qilu Hospital of 
      Shandong University, Jinan, China.
FAU - Liao, Lin
AU  - Liao L
AD  - Department of Endocrinology and Metabology, The First Affiliated Hospital of 
      Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, 
      Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong 
      Institute of Nephrology, Jinan, China.
AD  - Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20240327
PL  - Switzerland
TA  - Cardiorenal Med
JT  - Cardiorenal medicine
JID - 101554863
RN  - 0 (finerenone)
RN  - 0 (Naphthyridines)
RN  - 0 (Mineralocorticoid Receptor Antagonists)
SB  - IM
MH  - Humans
MH  - *Naphthyridines/therapeutic use/pharmacology
MH  - *Renal Insufficiency, Chronic/complications/physiopathology/drug therapy
MH  - *Mineralocorticoid Receptor Antagonists/therapeutic use/pharmacology
MH  - *Glomerular Filtration Rate/drug effects
MH  - Diabetes Mellitus, Type 2/complications/drug therapy/physiopathology
MH  - Kidney/physiopathology/drug effects
MH  - Racial Groups
OTO - NOTNLM
OT  - Chronic kidney disease
OT  - Diabetic kidney disease
OT  - Finerenone
OT  - Mineralocorticoid receptor antagonist
EDAT- 2024/03/28 00:45
MHDA- 2024/04/25 00:54
CRDT- 2024/03/27 19:26
PHST- 2023/11/23 00:00 [received]
PHST- 2024/03/03 00:00 [accepted]
PHST- 2024/04/25 00:54 [medline]
PHST- 2024/03/28 00:45 [pubmed]
PHST- 2024/03/27 19:26 [entrez]
AID - 000538347 [pii]
AID - 10.1159/000538347 [doi]
PST - ppublish
SO  - Cardiorenal Med. 2024;14(1):227-234. doi: 10.1159/000538347. Epub 2024 Mar 27.